Literature DB >> 20377409

Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.

Linda Aurpibul1, Thanyawee Puthanakit, Thira Sirisanthana, Virat Sirisanthana.   

Abstract

Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20377409     DOI： 10.1086/652150

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Sustained Responses to Measles Revaccination at 24 Months in HIV-infected Children on Antiretroviral Therapy in Kenya.

Authors:  Laura P Newman; Anne Njoroge; Amalia Magaret; Bhavna H Chohan; Veronicah W Gitomea; Anna Wald; Jonathan Gorstein; Julie Overbaugh; Dalton Wamalwa; Elizabeth Maleche-Obimbo; Ruth Nduati; Carey Farquhar
Journal:  Pediatr Infect Dis J       Date:  2017-12       Impact factor: 2.129

2.  Susceptibility to Measles Among Perinatally HIV-Infected Adolescents and Young Adults.

Authors:  Lee E Morris; Roberto Posada; Carole J Hickman; Donald R Latner; Tricia A Singh; Alyssa Rautenberg; Jennifer Jao; William J Bellini; Rhoda Sperling
Journal:  J Pediatric Infect Dis Soc       Date:  2013-09-24       Impact factor: 3.164

3.  T cell anergy and activation are associated with suboptimal humoral responses to measles revaccination in HIV-infected children on anti-retroviral therapy in Nairobi, Kenya.

Authors:  M B Buechler; L P Newman; B H Chohan; A Njoroge; D Wamalwa; C Farquhar
Journal:  Clin Exp Immunol       Date:  2015-07-02       Impact factor: 4.330

4.  Immunologic basis for revaccination of HIV-infected children receiving HAART.

Authors:  Kaitlin Rainwater-Lovett; William J Moss
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

5.  Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.

Authors:  Mark J Abzug; Min Qin; Myron J Levin; Terence Fenton; Judy A Beeler; William J Bellini; Susette Audet; Sun Bae Sowers; William Borkowsky; Sharon A Nachman; Stephen I Pelton; Howard M Rosenblatt
Journal:  J Infect Dis       Date:  2012-06-12       Impact factor: 5.226

Review 6.  Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.

Authors:  Nancy F Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2017-08-05

7.  [Persistence of hepatitis A virus antibodies after primary immunization and response to revaccination in children and adolescents with perinatal HIV exposure].

Authors:  Aída de Fátima Thomé Barbosa Gouvêa; Maria Isabel de Moraes Pinto; Maristela Miyamoto; Daisy Maria Machado; Silvana Duarte Pessoa; Fabiana Bononi do Carmo; Suênia Cordeiro de Vasconcelos Beltrão; Regina Célia de Menezes Succi
Journal:  Rev Paul Pediatr       Date:  2015-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.